Navigation Links
Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
Date:10/29/2012

BRAINTREE, Mass., Oct. 29, 2012 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today reported second quarter 2013 net revenue of $218.2 million, up 22%, GAAP net income of $6.5 million, down 53%, and diluted earnings per share of $0.25, down 53%.  Excluding restructuring, transformation, integration and transaction costs, adjusted net income was $23.5 million, up 26%, and adjusted earnings per share were $0.90, up 25%.  Organic net revenue, exclusive of the recently acquired whole blood business, was $189.6 million, up 6%. Excluding currency impacts, net revenue was up 22% in total and 6% on an organic basis.[1]

(Logo:  http://photos.prnewswire.com/prnh/20120206/NE47232LOGO )

Brian Concannon, Haemonetics' President and CEO, commented: "The highlights of our second quarter were the successful acquisition of the whole blood business and continued organic revenue growth in disposables across our entire product portfolio, especially in our Hospital business where 14% second quarter growth followed 11% growth in the first quarter.  Strong demand for the Cell Saver® Elite® and TEG® disposables, and growth in our OrthoPAT® business, provide strong evidence that our Hospital customers continue to embrace our Blood Management Solutions recognizing the inherent value proposition offered."STRATEGIC AND PRODUCT GROWTH HIGHLIGHTSHaemonetics continues to make progress expanding its business, reporting the following highlights:

  • 22% revenue growth including 6% organic revenue growth.
  • 7% revenue growth in plasma disposables.
  • 16% revenue growth in surgical disposables.
  • 23% revenue growth in diagnostic disposables.
  • 5% revenue growth in OrthoPAT disposables, a return to growth as
    '/>"/>

  • SOURCE Haemonetics Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related biology technology :

    1. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, ... peptides that are used solely in scientific experiments, is ... successful years in business, Maxim Peptide, which was created ... launched a new and updated website that now features ... section has been updated with fascinating articles about peptide ...
    (Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
    (Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
    (Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
    Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
    ... Pharmaceuticals, Inc., a,vertically integrated cGMP contract development ... Wood as Vice President, Business,Development. Ms. Wood ... including guiding Stason,s global business development,activities. Ms. ... experience in,sales, marketing, business and strategic planning, ...
    ... British Columbia researchers has developed a technique that controls ... superconductors, a procedure considered impossible for the past two ... the team deposited potassium atoms onto the surface of ... the scientists to continuously manipulate the number of electrons ...
    ... for Metabolic and Bariatric Surgery ... ... USGI Medical Inc. (USGI),announced today that leading experts presented clinical evidence ... an incisionless technique to reduce the size of the,gastric pouch and ...
    Cached Biology Technology:Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development 2UBC physicists develop 'impossible' technique to study and develop superconductors 2Studies Show USGI Medical's EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass 2
    (Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
    (Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
    (Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
    Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
    ... body's molecules controls the trafficking of T cells through the ... -- a crucial response that sometimes goes awry, attacking the ... control system -- composed of a fat-like compound called S1P ... cells from launching harmful reactions. But when the S1P traffic ...
    ... gene mutation that identifies the lung cancer patients most likely ... with a response to the drug cetuximab (Erbitux), according to ... the Journal of the National Cancer Institute. Both ... , Some patients with non?small-cell lung cancer (NSCLC) have mutant ...
    ... evidence that olfaction is uniquely a "dual" sense, in that ... arrives through the nose rather than the mouth. In the ... that the smell of chocolate activated different brain regions according ... through the mouth or through the nose. , In a ...
    Cached Biology News:Discovery of T-cell 'traffic control' boosts new drug promise 2Discovery of T-cell 'traffic control' boosts new drug promise 3Discovery of T-cell 'traffic control' boosts new drug promise 4Treatments have same target, different responses for lung cancer patients with genetic mutation 2Nose odors and mouth odors: The brain distinguishes 2Nose odors and mouth odors: The brain distinguishes 3
    b-Catenin (pSer675), phospho-specific...
    BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
    PKC (pSer345), phospho-specific...
    Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
    Biology Products: